GSP Neonatal Biotinidase and 13 more items

Revvity Health Sciences Inc has been awarded Virginia contract PO05468788 by the Department of General Services with a cumulative contract value of $2.88M. The award, effective September 14, 2026, encompasses the delivery of neonatal screening diagnostic kits and associated laboratory consumables to support newborn screening programs. The primary products include Galactosemia Screening Program (GSP) neonatal test kits for multiple analytes including biotinidase, galactose metabolism assessment (GALT), 17-hydroxyprogesterone (17OHP), immunoreactive trypsinogen (IRT), thyroid stimulating hormone (TSH), thyroxine (T4), and total galactose, with quantities ranging from 16 to 156 units per analyte.

All deliverables are designated for delivery to Leigh-Emma Lion at Room 150 (Darius Banks Room), with all line items directed to the same location within Virginia. The contract further includes supplementary laboratory supplies and reagents required for the diagnostic testing operations, including AutoDELFIA pipette tips, clear microplates in standard and U-bottom configurations, DELFIA inducer reagent concentrate, wash concentrate solutions, and specialized low-volume reagent tips. These supplies support the operational infrastructure necessary for the administration and processing of the neonatal screening kits throughout the contract period.